科创板第五套标准重启后首单IPO过会

Group 1 - The core viewpoint of the news is that Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the listing review by the Shanghai Stock Exchange, marking it as the first company to benefit from the reactivation of the fifth listing standard for unprofitable enterprises on the Sci-Tech Innovation Board [1][4] - Heyuan Biotechnology plans to raise 2.4 billion yuan through its IPO, with approximately 1.658 billion yuan allocated for the construction of a recombinant human albumin industrialization base, while the remaining funds will be directed towards new drug research and development and to supplement working capital [2][3] - The company has been focusing on the research of rice endosperm cell expression systems and the development of recombinant protein drugs since its establishment in 2006, with significant investments in R&D leading to continuous losses [2][4] Group 2 - The fifth listing standard emphasizes "market value + R&D," allowing unprofitable but high-growth technology innovation enterprises to list, particularly in the biopharmaceutical and semiconductor sectors [4][6] - Since the establishment of the Sci-Tech Innovation Board, 20 companies have successfully listed under the fifth standard, all being innovative biopharmaceutical enterprises, with a combined revenue exceeding 14 billion yuan in 2024, reflecting a growth of over 40% compared to 2023 [5][6] - Recent reforms aim to enhance the adaptability and inclusiveness of the Sci-Tech Innovation Board, with new measures introduced to support more frontier technology sectors such as artificial intelligence and commercial aerospace [6][7]